Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses immunologic biomarker findings in a study of mFOLFOX6 plus pembrolizumab (Keytruda) in colorectal cancer.
Matthew Farren, PhD
Advertisement
Articles by Matthew Farren, PhD
Advertisement
Latest Updated Articles
Immunologic Biomarker Findings for mFOLFOX6 and Pembrolizumab in CRCPublished: November 10th 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
